Weight-loss and progesterone treatments for early uterine lining disease
Treatments studied
Part of Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial studies a weight-management approach plus a progesterone-releasing IUD (LNG-IUS) and megestrol to treat endometrial atypical hyperplasia, a high-risk precancer of the uterine lining. It may help shrink or control the abnormal cells while supporting fertility or keeping the uterus.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 45
- Your body mass index (BMI) is 24 or higher
- A biopsy or procedure confirms endometrial atypical hyperplasia (uterine lining precancer) from pathology
- You strongly want fertility preservation or strongly want to keep your uterus
- You can reliably follow up on time at Obstetrics and Gynecology Hospital of Fudan University
- You do not have major uncontrolled organ problems (for example, significant liver or kidney dysfunction)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding GnRH medicine and letrozole to standard progestin treatment can better control early, low-risk endometrial cancer or atypical hyperplasia in people who are not obese. It may help some patients avoid progression while keeping the uterus, especially for those wanting future fertility.
This trial tests a combination of two hormone-blocking drugs (GnRHa plus letrozole) for women with early-stage, obesity-related endometrial cancer who haven't responded well to standard hormone therapy alone. The goal is to preserve the uterus and fertility while controlling the cancer.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
This trial tests a new treatment for very early endometrial cancer or a precancerous condition, aiming to help you avoid a hysterectomy and keep the chance of having children. It combines a medication (mazdutide) that helps with weight and hormone problems with a hormonal intrauterine device (LNG-IUS) to treat the lining of the womb.
This trial tests whether adding the weight-loss drug orlistat to standard hormone therapy can help shrink early-stage endometrial cancer or precancerous changes, so you can avoid having your uterus removed and still try for a baby later.
This study compares two approaches for women with obesity and early-stage endometrial cancer: having surgery right away versus going through a special weight-loss and health-optimization program before surgery. The goal is to see if preparing the body before surgery improves outcomes.
Hear when a new Atypical Endometrial Hyperplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.